Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: U.S. Surgical

This article was originally published in The Gray Sheet

Executive Summary

U.S. Surgical: Enters infusion port market with the acquisition of Device Labs, Inc.'s ChemoSite product line. The deal covers "all patents, patent applications, tooling and other assets" of the Medway, Massachusetts-based firm's infusion port business and gives USSC first refusal rights to all Device Labs' new products for the next five years. Terms of the deal were not disclosed. USSC is in due diligence on an agreement signed with American BioMed earlier this year that gave USSC the option to buy America BioMed's technologies for vascular stents, atherectomy and toposcopic catheters ("The Gray Sheet" May 8, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel